{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:16:44Z","timestamp":1774282604129,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.diabres.2021.108817","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:31:22Z","timestamp":1618533082000},"page":"108817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The current schemes of insulin therapy: Pro and contra"],"prefix":"10.1016","volume":"175","author":[{"given":"Matthew C.","family":"Riddle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108817_b0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2337\/diab.15.3.219","article-title":"Combined use of regular and crystalline protamine (NPH) insulins in the treatment of severe diabetes","volume":"15","author":"Oakley","year":"1966","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2021.108817_b0010","series-title":"Joslin\u2019s Diabetes Mellitus","first-page":"287","article-title":"Insulin in the treatment of diabetes","author":"Marble","year":"1971"},{"key":"10.1016\/j.diabres.2021.108817_b0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes: UKPDS 33","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108817_b0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"15","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0030","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2337\/dc13-2116","article-title":"for the DCCT\/EDIC Research Group. Updata on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study","volume":"37","author":"Lachin","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.2.2.154","article-title":"Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations","volume":"2","author":"Welborn","year":"1979","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0040","first-page":"47","article-title":"Insulin use and increased risk of mortality in type 2 diabetes: a cohort study","volume":"1","author":"Gamble","year":"2009","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabres.2021.108817_b0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01219790","article-title":"Diabetes and atherosclerosis\u2014the role of insulin","volume":"16","author":"Stout","year":"1979","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2021.108817_b0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2021.108817_b0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diab.35.5.530","article-title":"The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase","volume":"35","author":"The DCCT Research Group","year":"1986","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2021.108817_b0060","series-title":"Intensive insulin therapy","author":"Schade","year":"1983"},{"key":"10.1016\/j.diabres.2021.108817_b0065","first-page":"838","article-title":"Treatment of diabetes with insulin. From art to science","volume":"138","author":"Riddle","year":"1983","journal-title":"Western J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0070","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198805123181903","article-title":"Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus","volume":"318","author":"Polonsky","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/dci17-0049","article-title":"Maturation of CGM and glycemic measurements beyond HbA1c\u2014a turning point in research and clinical decisions","volume":"40","author":"Riddle","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0085","article-title":"New closed loop systems","author":"Boughton","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2021.108817_b0090","first-page":"469:-474","article-title":"Diabetes: the quest for basal normoglycemia","volume":"1","author":"Holman","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108817_b0095","first-page":"877","article-title":"VII: Study design, progress and performance","volume":"34","author":"UK Prospective Diabetes Study (UKPDS)","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2021.108817_b0100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2337\/diacare.13.6.676","article-title":"Evening insulin strategy","volume":"13","author":"Riddle","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(85)92029-X","article-title":"New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime","volume":"1","author":"Riddle","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108817_b0110","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"on behalf of the Insulin Glargine 4002 Study Investigators. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0115","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"on behalf of the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-na\u00efve people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0120","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Trial Investigators","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diabet.2017.04.007","article-title":"on behalf of the EDITION 3 study investigators","volume":"43","author":"Bolli","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2021.108817_b0130","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/dme.13390","article-title":"Review of basal-plus insulin regimen options for simpler insulin intensification in people with type 2 diabetes mellitus","volume":"34","author":"Raccah","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2021.108817_b0135","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/dom.12225","article-title":"Randomized, 1\u2014year comparison of three ways to initiate and advance insulin for type 2 diabtes: twice-daily premixed insulin versus basal insulin with either basal plus one prandial insulin or basal-bolus up to three prandial injections","volume":"16","author":"Riddle","year":"2014","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabres.2021.108817_b0140","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2337\/diacare.24.4.758","article-title":"Combination therapies with insulin in type 2 diabetes","volume":"24","author":"Yki-Jarvinen","year":"2001","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2021.108817_b0145","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc08-s231","article-title":"Combined therapy with insulin plus oral agents: is there any advantage?","volume":"31","author":"Riddle","year":"2008","journal-title":"An argument in favor Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2021.108817_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00325481.2020.1798099","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date","volume":"132","author":"Brunton","year":"2020","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabres.2021.108817_b0155","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabres.2021.108817_b0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2021.108817_b0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"The ORIGIN Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0170","unstructured":"Selvin E, Parrinello CM, Daya N, Bergenstal RM. Trends in insulin use and diabetes control in the U.S: 1988-1994 and 1999-2012"},{"key":"10.1016\/j.diabres.2021.108817_b0175","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.2337\/dc12-0270","article-title":"Plasma exposure to insulin glargine and its metabolites M1 and M2 aftr subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes","volume":"35","author":"Bolli","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041992","article-title":"Effect of insulin analogues on insulin\/IGF1 hybrid receptors: increased activation by glargine but not its metabolites M1 and M2","volume":"7","author":"Pierre-Eugene","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2021.108817_b0185","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2337\/dc12-2238","article-title":"Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial","volume":"36","author":"The ORIGIN Trial Investigators","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0190","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108817_b0195","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/dc09-1278","article-title":"for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) investigators","volume":"33","author":"Riddle","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0200","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc15-0598","article-title":"for the ACCORD investigators","volume":"38","author":"Siraj","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0205","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2337\/dci18-0052","article-title":"Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association","volume":"41","author":"Arslanian","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2337\/dc16-2380","article-title":"Basal glucose can be controlled, but the prandial problem persists\u2014it\u2019s the next target!","volume":"40","author":"Riddle","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0215","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month \u2018proof-of-concept\u2019 study","volume":"13","author":"Owens","year":"2011","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabres.2021.108817_b0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2213-8587(13)70144-X","article-title":"Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis","volume":"2","author":"Bell","year":"2014","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabres.2021.108817_b0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/dc19-0687","article-title":"Amount of dietary fat, postprandial glycemia, and insulin requirements in type 1 diabetes: a randomized within-subject trial","volume":"43","author":"Bell","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0230","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3945\/ajcn.2009.27720","article-title":"Food insulin index: physiologic basis for predicting insulin demand evoked by composite meals","volume":"90","author":"Bao","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabres.2021.108817_b0235","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.2337\/dc15-0429","article-title":"Food order has a significant impact on postprandial glucose and insulin levels","volume":"38","author":"Shukla","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/dia.2020.0360","article-title":"Impact of fast-acting insulin aspart on glycemic control in patients with type 1 diabetes using intermittent-scanning continuous glucose monitoring within a real-world setting: the GoBolus Study","volume":"23","author":"Danne","year":"2021","journal-title":"Diab Tech Ther"},{"key":"10.1016\/j.diabres.2021.108817_b0245","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc19-2550","article-title":"for the PRONTO-T2D investigators. Randomized double-blind clinical trial comparing ultra-rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D","volume":"43","author":"Blevins","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s001250051172","article-title":"Causes of weight gain during insulin treatment with and without metformin inpatients with type II diabetes","volume":"42","author":"Makimattila","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2021.108817_b0255","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.diabres.2004.07.005","article-title":"Weight gain during insulin therapy inpatients with type 2 diabetes mellitus","volume":"65S","author":"Heller","year":"2004","journal-title":"Diab Res Clin Prac"},{"key":"10.1016\/j.diabres.2021.108817_b0260","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc20-1232","article-title":"A meal detection algorithm for the artificial pancreas: a randomized controlled clinical trial in adolescents with type 1 diabetes","volume":"44","author":"Palisaitis","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0265","first-page":"E630","article-title":"Dose-response characteristics for effects of insulin on production and utilization of glucose in man","volume":"240","author":"Rizza","year":"1881","journal-title":"Am J Physiol"},{"key":"10.1016\/j.diabres.2021.108817_b0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in health humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.diabres.2021.108817_b0275","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.2337\/dc10-1126","article-title":"Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes. A pharmacokinetic and pharmacodynamics study","volume":"33","author":"Gagnon-Auger","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0280","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/dia.2019.0469","article-title":"Where do we stand with closed-loop systems and their challenges?","volume":"22","author":"Jackson","year":"2020","journal-title":"Diab Ther Tech"},{"key":"10.1016\/j.diabres.2021.108817_b0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/dc19-0895","article-title":"Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial","volume":"43","author":"Dovc","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0290","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2337\/dc19-2267","article-title":"Dual-hormone close loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single center, crossover, randomized controlled trial","volume":"43","author":"Wilson","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0295","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/dci19-0077","article-title":"Rediscovery of the second B-cell hormone: co-replacement with pramlintide and insulin in type 1 diabetes","volume":"43","author":"Riddle","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0300","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc18-1091","article-title":"Control of postprandial hyperglycemia in type 1 diabetes b 24-hour fixed-dose coadministration of pramlintide and regular human insujlin: a randomized, two-way crossover study","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0305","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/dc19-1922","article-title":"A novel dual-hormone insulin-and pramlintide artificial pancreas for type 2 diabetes: a randomized controlled crossover trial","volume":"43","author":"Haidar","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0310","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc09-0395","article-title":"Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes","volume":"32","author":"Riddle","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0315","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2337\/dc15-2782","article-title":"Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk","volume":"39","author":"The FLAT-SUGAR trial investigators","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108817_b0320","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2337\/dc20-2023","article-title":"Durable effects of iGlarLixi up to 52 weeks in type 2 diabetes: the LixiLan-G extension study","volume":"44","author":"Blonde","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721001765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:17:04Z","timestamp":1759173424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721001765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":64,"alternative-id":["S0168822721001765"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108817","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current schemes of insulin therapy: Pro and contra","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108817"}}